Capital International Investors Purchases 753,859 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Capital International Investors grew its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 35.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,863,249 shares of the biotechnology company's stock after purchasing an additional 753,859 shares during the period. Capital International Investors owned about 4.72% of Ascendis Pharma A/S worth $394,183,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in ASND. Capital International Sarl acquired a new stake in Ascendis Pharma A/S in the fourth quarter valued at approximately $3,277,000. Jump Financial LLC bought a new position in shares of Ascendis Pharma A/S in the 4th quarter valued at $1,666,000. Guggenheim Capital LLC boosted its holdings in shares of Ascendis Pharma A/S by 256.9% during the 4th quarter. Guggenheim Capital LLC now owns 7,249 shares of the biotechnology company's stock valued at $998,000 after acquiring an additional 5,218 shares in the last quarter. Mariner LLC grew its position in Ascendis Pharma A/S by 31.0% during the 4th quarter. Mariner LLC now owns 2,160 shares of the biotechnology company's stock worth $297,000 after acquiring an additional 511 shares during the last quarter. Finally, Sterling Capital Management LLC increased its holdings in Ascendis Pharma A/S by 19.0% in the 4th quarter. Sterling Capital Management LLC now owns 56,850 shares of the biotechnology company's stock worth $7,827,000 after purchasing an additional 9,065 shares in the last quarter.

Ascendis Pharma A/S Stock Performance

Shares of ASND stock traded down $3.90 during trading hours on Monday, hitting $161.15. 691,086 shares of the company were exchanged, compared to its average volume of 482,623. The company has a 50 day simple moving average of $152.70 and a two-hundred day simple moving average of $138.25. The firm has a market cap of $9.83 billion, a P/E ratio of -22.70 and a beta of 0.54. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $169.37.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, topping analysts' consensus estimates of ($1.32) by $0.64. As a group, sell-side analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on ASND shares. JPMorgan Chase & Co. boosted their price target on Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an "overweight" rating in a report on Tuesday, March 18th. Morgan Stanley set a $180.00 target price on shares of Ascendis Pharma A/S in a report on Tuesday, February 18th. UBS Group assumed coverage on shares of Ascendis Pharma A/S in a research note on Tuesday, January 7th. They set a "buy" rating and a $196.00 price target for the company. Evercore ISI boosted their price objective on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 18th. Finally, Cantor Fitzgerald raised their target price on Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 25th. Two analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $204.67.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.